Trial Information: 40 patients are being recruited for a Phase I study of the experimental new gamma-secretase inhibitor RO4929097 in combination with capecitabine, an oral DNA synthesis inhibitor already used in colon cancer and breast cancer. Eligible patients include those with any metastatic solid tumor cancer or lymphoma.
Background Information: Gamma secretase inhibitors target a particular protease complex in the cellular membrane, whose function is not yet fully understood. Earlier Phase I studies to establish safe dose levels noted responses in patients with melanoma and other diseases. It also showed substantial effectiveness in the laboratory setting.
The extremely broad nature of this trial should be taken as an indication that this is something of a shot in the dark by researchers who are seeking to identify which forms of cancer, if any, RO4929097 may be effective against.
Canadian Locations: Toronto, ON (Princess Margaret Hospital)
For more information, see ClinicalTrials.gov.
No comments:
Post a Comment